$24.05
8.59% yesterday
Nasdaq, Nov 15, 10:05 pm CET
ISIN
US07373V1052
Symbol
BEAM
Sector
Industry

Beam Therapeutics Inc Target price 2024 - Analyst rating & recommendation

Beam Therapeutics Inc Classifications & Recommendation:

Buy
56%
Hold
44%

Beam Therapeutics Inc Price Target

Target Price $49.20
Price $24.05
Potential
Number of Estimates 15
15 Analysts have issued a price target Beam Therapeutics Inc 2025 . The average Beam Therapeutics Inc target price is $49.20. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 18 analysts: 10 Analysts recommend Beam Therapeutics Inc to buy, 8 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Beam Therapeutics Inc stock has an average upside potential 2025 of . Most analysts recommend the Beam Therapeutics Inc stock at Purchase.

Sales and Margin forecast 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Revenue Million $ 377.71 50.72
520.01% 86.57%
EBITDA Margin -41.43% -796.77%
92.01% 1,823.36%
Net Margin -37.60% -767.98%
93.28% 1,942.73%

17 Analysts have issued a sales forecast Beam Therapeutics Inc 2024 . The average Beam Therapeutics Inc sales estimate is

$50.7m
Unlock
. This is
85.49% lower
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$75.0m 78.55%
Unlock
, the lowest is
$38.0m 89.13%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2023 $378m 520.01%
2024
$50.7m 86.57%
Unlock
2025
$57.5m 13.45%
Unlock
2026
$47.1m 18.21%
Unlock
2027
$74.9m 59.06%
Unlock
2028
$246m 228.99%
Unlock

5 Analysts have issued an Beam Therapeutics Inc EBITDA forecast 2024. The average Beam Therapeutics Inc EBITDA estimate is

$-404m
Unlock
. This is
151.26% lower
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-389m 141.99%
Unlock
, the lowest is
$-416m 158.37%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2023 $-156m 50.47%
2024
$-404m 158.27%
Unlock
2025
$-432m 6.91%
Unlock
2026
$-467m 8.06%
Unlock
2027
$-341m 26.96%
Unlock
2028
$-245m 28.18%
Unlock

EBITDA Margin

2023 -41.43% 92.01%
2024
-796.77% 1,823.36%
Unlock
2025
-750.83% 5.77%
Unlock
2026
-992.04% 32.13%
Unlock
2027
-455.53% 54.08%
Unlock
2028
-99.44% 78.17%
Unlock

17 Beam Therapeutics Inc Analysts have issued a net profit forecast 2024. The average Beam Therapeutics Inc net profit estimate is

$-390m
Unlock
. This is
168.06% lower
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-360m 147.73%
Unlock
, the lowest is
$-415m 185.80%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2023 $-142m 58.35%
2024
$-390m 174.30%
Unlock
2025
$-397m 1.95%
Unlock
2026
$-394m 0.79%
Unlock
2027
$-358m 9.12%
Unlock
2028
$-249m 30.58%
Unlock

Net Margin

2023 -37.60% 93.28%
2024
-767.98% 1,942.73%
Unlock
2025
-690.09% 10.14%
Unlock
2026
-837.10% 21.30%
Unlock
2027
-478.30% 42.86%
Unlock
2028
-100.92% 78.90%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Earnings Per Share $ -1.72 -4.72
58.35% 174.42%
P/E negative
EV/Sales 24.21

17 Analysts have issued a Beam Therapeutics Inc forecast for earnings per share. The average Beam Therapeutics Inc <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

$-4.72
Unlock
. This is
168.18% lower
Unlock
than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is
$-4.36 147.73%
Unlock
, the lowest is
$-5.03 185.80%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2023 $-1.72 58.35%
2024
$-4.72 174.42%
Unlock
2025
$-4.81 1.91%
Unlock
2026
$-4.77 0.83%
Unlock
2027
$-4.34 9.01%
Unlock
2028
$-3.01 30.65%
Unlock

P/E ratio

Current -13.66 157.25%
2024
-5.10 62.66%
Unlock
2025
-5.00 1.96%
Unlock
2026
-5.04 0.80%
Unlock
2027
-5.55 10.12%
Unlock
2028
-7.99 43.96%
Unlock

Based on analysts' sales estimates for 2024, the Beam Therapeutics Inc stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

24.21
Unlock
and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of
39.27
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 3.51 70.33%
2024
24.21 589.68%
Unlock
2025
21.34 11.86%
Unlock
2026
26.09 22.27%
Unlock
2027
16.40 37.13%
Unlock
2028
4.99 69.60%
Unlock

P/S ratio

Current 5.70 74.28%
2024
39.27 589.37%
Unlock
2025
34.61 11.86%
Unlock
2026
42.32 22.27%
Unlock
2027
26.60 37.13%
Unlock
2028
8.09 69.60%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today